| Biomarker ID | 683 |
| PMID | 21741162 |
| Year | 2011 |
| Biomarker | thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(THBS1):- Integrin cell surface interactions, Beta-3 integrin cell surface interactions, Malaria, Senescence and autophagy, TGF-beta regulation of skeletal system development Pathways Include(CRP):-Vitamin B12 metabolism,Selenium pathway, Folate metabolism,Interleukin-6 signaling pathway,Complement cascade Pathways Include (NECTIN1):- Cell junction organization, Adherens junction, Cell adhesion molecules (CAMs), Herpes simplex virus 1 infection, PAK Pathway |
| Experiment | Overall Survival Vs No Survival (24 months) |
| Type of Biomarker | Prognostic |
| Cohort | 57 patients with prostate cancer were included in the study. At the time of the analysis, 65% of patients had died (n = 37); of these, 89% (n = 33) died from mCRPC. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.943 (95% CI: 0.894–0.985) |
| Accuracy | 94% |
| Level Of Significance | NA |
| Method Used | ELISA + Mass Spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | THBS1, CRP, NECTIN1, MME, EFNA5 |